Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human (FIH), Multicenter, Open-Label, Phase Ia (Dose Escalation)/Phase Ib (Dose Expansion) Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

NCT06190886 is registered in ClinicalTrials.gov with Proviva Therapeutics, Inc. as lead sponsor.

NCT NCT06190886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06190886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human (FIH), Multicenter, Open-Label, Phase Ia (Dose Escalation)/Phase Ib (Dose Expansion) Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
Lead sponsor
Proviva Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
June 11, 2024
Completion date
July 24, 2026
Enrollment
26 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer, solid tumor